Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 16/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22002748 | 0.82 | NLRP3 (0.48) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL22002684 | 0.80 | NLRP3 (0.45) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL22012490 | 0.77 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL6866811 | 0.77 | NLRP3 (0.57) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25831042 | 0.74 | NLRP3 (0.50) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL22013712 | 0.74 | NLRP3 (0.54) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL20194506 | 0.73 | NLRP3 (0.53) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL21646588 | 0.72 | NLRP3 (0.49) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL22266139 | 0.72 | ALDH1A1 (0.53) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25015053 | 0.72 | NLRP3 (0.41) | NLRP3ATMSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ATM 3677/4885SMN1; SMN2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.